REHOVOT, Israel, April 4, 2022 /PRNewswire/ -- NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation, announced positive, long-term safety and tolerability data for ND0612 at the American Academy of Neurology Annual Meeting (in Seattle, April 2-7, and virtually, April 24-27 ). This investigational drug-device combination product provides minimally invasive, continuous subcutaneous infusion of liquid levodopa/carbidopa for people with Parkinson's disease (PD) experiencing motor fluctuations.